To test the COX-2
inhibitor called nimesulide against cancerous pancreatic cells, Guido Eibl of the University of California, Los Angeles School of Medicine and his colleagues applied the drug to cells from COX-2
-positive and COX-2
-negative pancreatic tumors.
While phase II trials have compared the drug to placebos, the phase III trials focus on the safety and effectiveness of cox-2
inhibitors compared to NSAIDs.
Key clinical trials, including the evidence leading up to Mercks decision to withdraw Vioxx and results from various long-term clinical trials involving other members of the Cox-2
class, are examined.
Meanwhile, Simmons says there could also be variants of COX-2
susceptible to acetaminophen.
The picture that emerges is one in which a majority of primary care physicians continue to believe that the COX-2
Inhibitor drug category presents important treatment options for patients who do not have cardiovascular disease or hypertension, " Anne Goodrich, Pri-Med Institute director of research, said.
To verify earlier studies that hinted at a Cox-2
role in stomach cancer, the Finnish scientists examined tumors from 43 patients with a type of stomach cancer that resembles colon cancer.
The association of Asacard with a branded product such as a selective COX-2
inhibitor or even standard NSAID's could permit patients to benefit from the efficacy of these anti-inflammatory drugs, while lessening the risk of thrombosis and reducing the side effects associated with aspirin itself.
To determine how APHS works, the researchers created mutant COX-2
enzymes and measured the compound's ability to block their action.
research is auspicious, and any gains in colon cancer treatment will probably apply to rectal cancer as well, DuBois says.
Post recall, gaining the approval of the Food and Drug Administration (FDA) for new Cox-2
inhibitors is likely to be a long-drawn out process," says Frost & Sullivan Research Analyst Elisa Perez.
The research service "Vioxx Recall - Revenue and Impact Analysis on Cox-2
Inhibitors Markets" includes: annual cost of therapy for Cox-2
inhibitors by indication, patients switch to other Cox-2
inhibitors and traditional NSAIDs, physician recommendations on patient education after a recall, forecasts for patients and revenues before and after the recall, adverse effects of Cox-2
inhibitors and traditional NSAIDs, and key indications for Vioxx, Celebrex, or Bextra.
This report was written to help all involved in the drug development sector to understand the biology surrounding the COX-2
inhibitor class and the (pre)clinical profiles of COX-2
inhibitors in advanced development or on the market.
In the wake of Merck's announcement Pfizer affirmed the safety of their COX-2
inhibitor and European regulators stated that they will now be looking at other COX-2
inhibitors more carefully, impacting on newer agents such as Merck's Arcoxia, and Novartis' Prexige; and others are suggesting that now is the time to push forward other therapeutic classes that can reduce the pain of osteoarthritis such as the NO-NSAIDs and LOX/COX inhibitors as well as osteoarthritis and rheumatoid disease modifying agents.
Prime Therapeutics (Prime), a pharmacy benefits manager, and Blue Cross and Blue Shield of Nebraska implemented a Cox-2
pre-authorization program that effectively decreased pharmacy costs.
Findings reported in a study published today by The American Journal of Managed Care call into question the cost effectiveness of the new, more expensive COX-2